CURRENT CORE RESEARCH LINES AND POTENTIAL FUTURE CONTRIBUTIONS
Economic evaluation of health technologies (dynamic and Markovian modelling of diseases, budget impact analysis of technologies, costs calculations, etc.).
Studies of the efficiency of health organizations (data envelopment analysis).
Theoretical economic decision making models for health policy and management (patents, research activities of health technology industry, price and reimbursement of drugs, risk-sharing agreements, personalized medicine implementation, etc.).
Economics of drugs (analysis of the pharmaceutical sector, time series analysis of trends, pricing, consumption, research and development analysis, etc.).
Quantitative models applied to the health sector (econometric and time series analysis).
SOME INDICATORS OF THE ACTIVITIES OF THE GROUP
Direction of PhD dissertations: 16.
Total number of indexed publications: about 250
Total publications in the first quartile (JCR-Q1): 53
Participation in national and international congresses: more than 200
Professor Fernando Antoñanzas belongs to the Scientific Panel for Health of the European Commission for the strategic planning of health research for the horizon 2015-2020.
EXPERIENCE IN RESEARCH PROJECTS (last years. participation or leading research group)
National & Regional Projects
European Projects
Current
Evidence-based Participatory Decision Making for Cancer Prevention through implementation research . (ONCODIR) European Commission: 101104777; Call: HORIZON-MISS-2022-CANCER-01
A European “shield” against colorectal cancer based on novel, more precise and affordable risk-based screening methods and viable policy pathways. (ONCOSCREEN). European Commission: 101097036; Call: HORIZON-MISS-2021-CANCER-02
The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use. European Commission: 820755; Call: H2020-JTI-IMI2-2017-13-two-stage. 2019-2023
Anteriores
La Medicina Personalizada y los Contratos de Riesgo Compartido como nuevos paradigmas de gestión sanitaria: modelos económicos teóricos y aplicaciones. Proyecto Mineco código ECO2016-78685-R, 2016-2019
Building a tool to evaluate and improve health investments in screening and diagnosis of disease. European Commission: 223533 Health-F2-2009223533 (FP7-Health-2007-B), 2010-2013
SOME CONTRACTS OF TRANSFERENCE OF KNOWLEDGE
Dynamic economic evaluations of Prevenar 13. Pfizer, 2013 and 2015.
Economic evaluation of health technologies. Novartis Pharma, 2011.
Long term health care in Western health systems. Ministry of Health, 2008.
Trends of health systems development. Ministry of Health, 2007.
SOME RECENT PUBLICATIONS
Antoñanzas, F., Juárez-Castelló, C. & Rodríguez-Ibeas, R. (2023) Tenders for generics and biosimilars: a challenging purchasing policy. European Journal of Health Economics. https://doi.org/10.1007/s10198-023-01580-z
Antoñanzas, F.Juárez-Castelló, CA & Rodríguez-Ibeas, R. (2022). Does diagnostic testing always decrease antibiotics prescriptions? European Journal of Health Economics. https://doi.org/10.1007/S10198-022-01488-0
Lorente, R., & Antonanzas, F. (2022). Seeking efficiency gains outside drugs and diagnostics. En European Journal of Health Economics (Vol. 23, Número 5, pp. 759-761). Springer Science and Business Media Deutschland GmbH. https://doi.org/10.1007/s10198-022-01456-8
Rojas-Garcia, P., van der Pol, S., van Asselt, A. D. I., Postma, M. J., Rodríguez-Ibeas, R., Juárez-Castelló, C. A., González, M., & Antoñanzas, F. (2022). Diagnostic testing for sepsis: A systematic review of economic evaluations [Review of Diagnostic testing for sepsis: A systematic review of economic evaluations]. Antibiotics, 11(1). MDPI. https://doi.org/10.3390/ANTIBIOTICS11010027
van der Pol, S.,Rojas Garcia, P., Antoñanzas Villar, F.van Asselt, A.D.I. & Postma, M.J.(2021) Health-Economic Analyses of Diagnostics: Guidance on Design and Reporting. PharmacoEconomics.https://doi.org/10.1007/s40273-021-01104-8
Rodriguez, R. Antonanzas, F. Juárez-Castelló, C.A. (2021). "Using point-of-care diagnostic testing for improved antibiotic prescription: an economic
model" Health Economics Review
11, 29 https://doi.org/10.1186/s13561-021-00326-y
van der Pol, S., Rojas Garcia, P. Postma, M.J. Antoñanzas, F. & van Asselt, A.D.I. (2021) "Economic Analyses of Respiratory Tract Infection Diagnostics: A Systematic Review". PharmacoEconomics (2021). DOI:10.1007/s40273-021-01054-1
Rojas García, P. van der Pol, S. van Asselt, A. Postma, M. Rodríguez-Ibeas, R. Juárez-Castelló, C.A. González, M. Antoñanzas, F. (2021). "Efficiency of Diagnostic Testing for Helicobacter pylori Infections—A Systematic Review" Antibiotics 10, no. 1: 55. DOI:10.3390/antibiotics10010055
Capri, S. Antonanzas, F. (2020) "Efficiency ratio and rocketing drug prices: old concerns and new possibilities" European Journal of Health Economics 21(9):1273-1277 DOI:10.1007/s10198-020-01194-9
Rojas P, Antoñanzas F (2020). Policies to reduce antibiotic consumption: The impact in the Basque Country. Antibiotics, 9(7), 423, DOI:10.3390/antibiotics9070423
Sipido K, Antoñanzas F, Celis J, Degos L, Frackowiak, Fuster V et al (2020. Overcoming fragmentation of health research in Europe: lessons from COVID19. The Lancet published on line June 16, 2020. DOI: 10.1016/S0140-6736(20)31411-2
Mosegui G, Araujo R, Vianna C, Antoñanzas F, Catao T (2020). Reflections and perspectives on biosimilars in Brazil. International Journal of Pharmacy and Pharmaceutical Sciences; vol 12(7), DOI:10.22159/ijpps.2020v12i7.37903
Aballéa, S. Thokagevistk, K. Velikanova, R. Simoens, S. Annemans, L. Antonanzas, F. Auquier, P. François, F.
Fricke, F.U. Malone, D. Millier, A. Persson, U. Petrou, S. Dabbous, O.
Postma, M. & Toumi, M. (2020) Health economic evaluation of gene replacement therapies:
methodological issues and recommendations, Journal of Market Access & Health Policy, 8:1,
1822666, DOI: 10.1080/20016689.2020.1822666
Antoñanzas, F., Juárez-Castelló, C.A. & Rodríguez-Ibeas, R. (2019) Pre-approval incentives to promote adoption of personalized medicine: a theoretical approach. Health Economics Review 9, 28. DOI:10.1186/s13561-019-0244-8
